Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Operating Margin: 2009-2025

Historic Operating Margin for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -83.06%.

  • China Pharma Holdings' Operating Margin rose 1558.00% to -83.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -79.83%, marking a year-over-year increase of 272.00%. This contributed to the annual value of -101.32% for FY2024, which is 6208.00% down from last year.
  • As of Q3 2025, China Pharma Holdings' Operating Margin stood at -83.06%, which was down 30.66% from -63.57% recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Operating Margin peaked at -20.28% during Q1 2023, and registered a low of -150.44% during Q2 2024.
  • For the 3-year period, China Pharma Holdings' Operating Margin averaged around -71.94%, with its median value being -66.76% (2025).
  • As far as peak fluctuations go, China Pharma Holdings' Operating Margin slumped by 10,888bps in 2024, and later skyrocketed by 8,687bps in 2025.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Operating Margin stood at -22.45% in 2021, then slumped by 1,757bps to -40.02% in 2022, then plummeted by 1,508bps to -55.10% in 2023, then crashed by 5,037bps to -105.47% in 2024, then spiked by 1,558bps to -83.06% in 2025.
  • Its Operating Margin stands at -83.06% for Q3 2025, versus -63.57% for Q2 2025 and -66.76% for Q1 2025.